Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Feb;44(2):123-130.
doi: 10.1007/s40261-023-01338-8. Epub 2024 Jan 9.

A Real-World Observational Study to Evaluate the Safety and Effectiveness of Fluticasone Furoate-Oxymetazoline Fixed Dose Combination Nasal Spray in Patients with Allergic Rhinitis

Meenesh R Juvekar  1 , Gauri Kapre Vaidya  2 , Aniruddha Majumder  3 , Amod D Pendharkar  4 , Anthony Irudhayarajan  5 , Avijit Kundu  6 , D Ramesh  7 , J Dheeraj Kumar  8 , B Jagannatha  9 , Joseph Mathew  10 , Mahesh P Nikam  11 , Madhuri Mehta  12 , Neeraj Chawla  13 , Priti Hajare  14 , P G Chandre Gowda  15 , P V L N Murthy  16 , Suma Moni Mathew  17 , Makarand V Damle  18 , Chandra Kant  19 , Arun B Nair  20 , Ashok Jaiswal  21 , Ravi T Mehta  22
Affiliations
Observational Study

A Real-World Observational Study to Evaluate the Safety and Effectiveness of Fluticasone Furoate-Oxymetazoline Fixed Dose Combination Nasal Spray in Patients with Allergic Rhinitis

Meenesh R Juvekar et al. Clin Drug Investig. 2024 Feb.

Abstract

Background: Allergic rhinitis (AR) has shown an increasing prevalence leading to a considerable medical and social burden. Nasal congestion is the cardinal symptom of AR, and the upper respiratory tract is most affected by this long-lasting ailment. Intranasal corticosteroids alleviate nasal congestion, along with other symptoms of AR, but their effect is not evident immediately. Oxymetazoline has a rapid onset of action, but its use should be limited to 3-5 days.

Objective: The study aimed to evaluate the safety and effectiveness of the fixed-dose combination nasal spray containing fluticasone furoate and oxymetazoline hydrochloride (FF + OXY) 27.5/50 mcg once daily in patients with AR in a real-world clinical setting.

Methods: The study was a prospective, open-label, single-arm, multicenter, real-world observational study conducted in patients with AR for a period of 28 days. Patients (n = 388) with a diagnosis of AR were treated with a combination of FF + OXY nasal spray. Total nasal symptom score (TNSS), total ocular symptom score (TOSS) and total symptom score (TSS) were documented at baseline and at the end of study period. The overall effectiveness of treatment with FF + OXY was rated by the investigators as very good/good/satisfactory/poor (4-point Likert scale) for each patient.

Results: Treatment with FF + OXY resulted in significant reduction in the TNSS, TOSS and TSS, from 7.18 ± 3.38 at baseline to 0.20 ± 0.84 (p < 0.001), from 2.34 ± 2.29 at baseline to 0.09 ± 0.53 (p < 0.001), from 9.51 ± 4.94 at baseline to 0.29 ± 1.32 (p < 0.001) at 28 days respectively. With respect to effectiveness, the investigators reported very good effectiveness in 52.12% of patients. No serious adverse events were reported.

Conclusion: The fixed-dose combination of once-daily fluticasone furoate and oxymetazoline hydrochloride nasal spray 27.5/50 mcg was effective in relieving the nasal congestion and reduction of TNSS, TOSS and TSS in patients suffering from AR. The combination was safe and well tolerated with no rebound congestion throughout the treatment period.

PubMed Disclaimer

References

    1. Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Canonica GW, Melén E, Palomares O, Scadding GK, Togias A, Toppila-Salmi S. Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):1–7. https://doi.org/10.1038/s41572-020-00227-0 . - DOI
    1. Ghoshal AG, Ravindran GD, Gangwal P, et al. The burden of segregated respiratory diseases in India and the quality of care in these patients: results from the Asia-Pacific Burden of Respiratory Diseases study. Lung India. 2016;33(6):611–9. https://doi.org/10.4103/0970-2113.192878 . - DOI - PubMed - PMC
    1. Khanna P, Shah A. Categorization of patients with allergic rhinitis: a comparative profile of “sneezers and runners” and “blockers.” Ann Allergy Asthma Immunol. 2005;94(1):60–4. https://doi.org/10.1016/S1081-1206(10)61287-2 . - DOI - PubMed
    1. Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW, Peters AT, Rondon C, Togias A, Cox LS. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70(5):474–94. https://doi.org/10.1111/all.12573 . - DOI - PubMed
    1. Nafees S, Sudhakar KVK. A study of impact of allergic rhinitis on quality of life of people in Western U.P. Asian J Med Res. 2022;11(2):53–7.

Publication types

MeSH terms

LinkOut - more resources